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ProgrammedElectrical Stimulation
for Risk Assessment in
Brugada Syndrome
Time to Change the Guidelines?*
Kelley P. Anderson, MD
Marshfield, Wisconsin
Brugada syndrome (BrS) is a rare inheritable disorder
identified by characteristic abnormalities in the anterior
electrocardiographic (ECG) leads (1). The main clinical
problem is sudden cardiac death (SCD). The only accepted
form of SCD prevention is an implantable cardioverter
defibrillator (ICD). However, the patient who undergoes
ICD implantation is exposed to pain, inconvenience, and a
wide variety of serious mechanical and psychological com-
plications that might have a major negative impact on
quality of life, and result in considerable cost to healthcare
systems.
See page 37
The clinician must decide whether or not to recommend
ICD insertion and must justify the decision and reassure all
those concerned—not only the patient but also family,
friends, and other healthcare providers—that that the risk of
SCD warrants the adverse effects of ICD therapy or that the
risk of SCD for the patient is so low that the disadvantages
of an ICD outweigh the benefit. This is often difficult,
because any risk of SCD is intolerable to some and likely
contributes to the observation that the majority of patients
who receive ICDs for primary prevention in BrS never
receive a life-saving intervention. This has driven an intense
effort to identify risk factors for SCD in patients with BrS.
Programmed electrical stimulation (PES)—an invasive test,
which is used to determine whether sustained ventricular
tachyarrhythmia (VTA) that often requires countershock
can be induced—has been used to evaluate the disorder
since it was described in 1992 (1). However, several inves-
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contents of this paper to disclose.tigators and laboratories have not found PES to be helpful
in identifying BrS patients at risk for SCD. Acknowledging
the debate and lack of definitive evidence, the committee
that produced the American College of Cardiology/
American Heart Association/European Society of Cardiol-
ogy 2006 Guidelines for Management of Patients With
Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death assigned a Level IIb recommendation (i.e.,
that PES “may be considered for risk stratification in
asymptomatic Brugada syndrome patients with spontaneous
ST-segment elevation.”) (2). In 2006 and 2007, 2
meta-analyses were published that concluded that PES did
not provide significant prediction of arrhythmic events in
patients with BrS (3,4). Despite the lack of uniform
supporting evidence and the practice guideline recommen-
dations, PES continues to be used for risk stratification of
symptomatic and asymptomatic BrS patients and those with
and without spontaneous ST-segment elevation.
In this issue of the Journal, Priori et al. (5) report the
findings of the PRELUDE (PRogrammed ELectrical
stimUlation preDictive valuE) study. The investigators
enrolled 308 patients with spontaneous or pharmacologi-
cally induced type I BrS ECG pattern who had no history
of cardiac arrest or sustained VTA. A uniform stimulation
protocol at least as aggressive as those previously reported
was specified in advance, consisting of 2 drive cycle lengths
with up to 3 ventricular extrastimuli at 2 right ventricular
sites with the coupling interval of the last (S4) extrastimulus
shortened to refractoriness. During a mean follow-up of 36
months, 14 of 308 patients (4.5%; 1.5% annually) experi-
enced the primary endpoint (appropriate ICD intervention
[n  13] or resuscitated cardiac arrest [n  1]). There were
o deaths. The main finding was that arrhythmia-free
urvival was nearly identical between those with and without
nduced sustained VTA. Discrimination was not improved
f only patients with VTA induced by a less aggressive
timulation program (1 or 2 extrastimuli) were considered.
rogrammed electrical stimulation was insensitive at pre-
icting those with arrhythmic events (sensitivity 36%) and
ot specific (59%). Sensitivity declined to 25%, with a small
ncrease in specificity (74%), when including only those with
nduction related to 1 or 2 extrastimuli. The event rate after
pproximately 4 years was slightly but not significantly
orse among non-inducible patients (4.9%), compared with
nducible patients (3.9%). Therefore, a negative PES re-
ponse was not associated with a low risk of an arrhythmic
vent. When the response to PES was included in multi-
ariate analyses with other risk factors demonstrating sig-
ificant predictive value (spontaneous BrS Type I ECG
attern, syncope, ventricular refractory period [VRP] 200
s and 2 spikes in the QRS complex in leads V1 to V3
[QRS fragmentation (QRS-f)]), no significant predictive
value of inducibility status was identified. Moreover, the
PRELUDE investigators demonstrated that the immediate
reproducibility of a positive PES was only 34%.
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December 27, 2011/January 3, 2012:46–8 Risk Assessment in Brugada SyndromeThe PRELUDE investigators found significant indepen-
dent predictive value for other covariates supported by
findings of significant discrimination of the cumulative
probability of arrhythmic event outcomes. Sensitivities were
greater for each of the other covariates examined, compared
with PES. The highest sensitivity was observed for sponta-
neous BrS Type I ECG pattern (92.9%), although specific-
ity was low (47.5%). The highest specificities were observed
for QRS-f (93.5%) and the combination of syncope and
spontaneous Type 1 ECG pattern (90.5%), but both had
relatively low sensitivity (both 42.9%). The absence of
spontaneous BrS ECG pattern and VRP 200 ms demon-
strated greater cumulative probability of arrhythmic event-
free survival than a negative PES response, although statis-
tical significance was not evaluated.
The PRELUDE investigators used a prospective registry
design with pre-specified inclusion and exclusion criteria
and uniform PES protocols and endpoints. These tech-
niques reduce but might not eliminate recruitment bias, data
errors, and protocol violations. In an ideal world where
funding was commensurate with clinical impact, registries
such as the PRELUDE registry would provide access to
detailed information with regard to operations and execu-
tion, including flow of patients from screening to end of
follow-up with documentation of reasons for exclusions and
loss to follow-up, methods of data verification, and results of
audits that allow estimation of errors in data and protocol
violations. Although implied, it was not stated that this was
an inception cohort. A bias favoring ICD therapy was
suggested by the fact that 78% of the 126 patients who had
a VTA induced with PES underwent ICD insertion com-
pared with 21% of noninducible patients. The PRELUDE
investigators used a surrogate endpoint “arrhythmic events”
defined as “occurrence of ventricular fibrillation or appro-
priate ICD interventions based on the clinical judgment of
the cardiologist in charge of the patient.” Assessment of
endpoints by independent observers unaware of clinical data
would be more objective. Moreover, it has been shown in
large ICD trials of patients with dilated or ischemic cardio-
myopathies that appropriate ICD therapy rates are 2 to 3
times higher than SCD events in control (non-ICD)
subjects (6). The mechanism for this phenomenon (i.e., a
proarrhythmic effect or treatment of events that would have
terminated spontaneously) is not known. It is also unknown
if this phenomenon occurs in BrS patients with ICDs.
Either mechanism would result in an ascertainment bias
favoring detection of arrhythmic events in patients with
ICDs as well as those with inducible VTA, most of whom
(78%) had an ICD. Therefore, it is possible that the rate of
arrhythmic events was overestimated in PES-positive pa-
tients and/or underestimated in PES-negative patients (21%
with ICDs) in the PRELUDE study. The PRELUDE
investigators did not report the occurrence of potentially
arrhythmic syncopal events during the follow-up period,
which might have provided insight on the occurrence ofself-terminating arrhythmias in the patients without ICDs
and syncope mechanisms in those with ICDs.
In addition to the findings for PES, the investigators
presented interesting findings with regard to 2 novel risk
predictors. The measurement referred to as “VRP 200”
(ventricular refractory period 200 ms) demonstrated a
relatively high sensitivity (78.6%), modest specificity
(62.9%), and high cumulative probability of arrhythmia
events, judging from the Kaplan-Meier plot in Figure 5A of
Priori et al. (5). This measurement was obtained with the
protocol typically used in clinical laboratories for arrhythmia
induction. However, VRP is sensitive to autonomic tone as
well as the duration of the drive train and previous ventric-
ular extrastimuli (7). Greater precision in the measurement
might be obtained with autonomic blockade and by a
continuous stable drive train with initial extrastimuli deliv-
ered within the refractory period and gradually extended
with no compensatory pause to avoid perturbing the under-
lying cycle length. In addition, the arbitrarily selected
200-ms threshold might not be the optimal cut point,
because it dichotomizes patients on the basis of a single
coupling interval decrement (10 to 20 ms). Additional data
analysis from the PRELUDE registry and confirmatory stud-
ies are needed before this measurement can be recommended.
QRS fragmentation was the most specific risk factor
(93.5%), with a relatively high cumulative probability of
arrhythmic events, and it was associated with the lowest
number of patients needed to treat with an ICD to save a
life (4.7, assuming an arrhythmic event is a perfect surrogate
for death). High-frequency deflections (fragmentation,
spikes) in extracellular potentials probably result from asyn-
chronous electrical activation, often due to nonuniform
anisotropic propagation. It has long been known that the
right ventricular outflow tract is a region prone to nonuni-
form activation that can modulate repolarization properties
and could result in re-entry in some conditions (8). Because
BrS is associated with abnormalities in repolarization and
propagation and it has been reported that ventricular ar-
rhythmias might originate from the right ventricular out-
flow tract in this disorder, an association between QRS-f
and arrhythmic events in BrS has biological plausibility (9).
However, consistent recording of high-frequency deflec-
tions in ECGs requires careful attention to filter settings,
amplification, sampling rate, and impedance (9).
Despite some concerns with regard to the design and
execution of the PRELUDE study, there were notable
strengths compared with some previous studies that used
retrospectively collected baseline and follow-up data and
used a variety of stimulation protocols (3–5). Despite design
differences, the PRELUDE study confirmed several previ-
ous studies and the 2 meta-analyses in the main finding that
PES does not provide significant SCD risk prediction or
absence of SCD risk. It also confirmed greater risk in
patients with a spontaneous (vs. drug-induced) BrS ECG
pattern and in patients with a history of syncope (3–5).
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Risk Assessment in Brugada Syndrome December 27, 2011/January 3, 2012:46–8The PRELUDE investigators have provided the most
rigorous evidence to date with regard to the poor utility of
PES for risk stratification of patients with BrS and have set
a high standard for new studies. Nevertheless, there is no
unequivocal explanation for why some investigators report
that PES has predictive value, in contradiction to the
PRELUDE study and previous investigations (3–5). One
cannot exclude the possibility that some unidentified differ-
ences in patient characteristics, induction techniques, treat-
ments, or follow-up protocols are responsible for the discrepant
findings. Nevertheless, the weight of available evidence sug-
gests that the use of PES in patients with BrS receive a Class
III level recommendation (risk  benefit), because of the
potential for harm from both the invasive nature of the
procedure and the potential for misleading information. Cli-
nicians and investigators who believe in the continued use of
PES should enroll patients in rigorously designed inception
cohort prospective registries or trials to develop an up-to-date
evidence-base to support their practice. Although the observa-
tions of the PRELUDE investigators signal the demise of PES
for BrS, they have provided promising new opportunities for
risk stratification in this challenging disorder.
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